Previously reported analyses from SHARP showed no significant reductions in any of the pre-specified measures of renal disease progression (end-stage renal disease defined as commencement of maintenance dialysis or transplantation) [9], and exploratory analyses showed no effect on urinary albumin creatinine ratio at 2.5 years [43]. This evidence concerns the gene ALB and stage 5 chronic kidney disease.